Intervention after PSA failure: Examination of intervention time and subsequent outcomes from a prospective patient database

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 2, 2004, Pages 463-469

  Kim Sing, Charmaine ^a   Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Prostate neoplasms; PSA failure; Radiotherapy

Indexed keywords

BIOCHEMISTRY; DRUG DOSAGE; ONCOLOGY; RADIOTHERAPY; TUMORS;

ANDROGEN ABLATION; EXTERNAL BEAM RADIOTHERAPY (EBRT); MULTIVARIATE ANALYSIS (MVA); PROSTATE CANCER;

PATIENT MONITORING;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANADA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DATA BASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECURRENCE; REFERENCE VALUES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 4544296273     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.03.004     Document Type: Article

References (23)

1. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy An analysis of long-term outcome [see comments]. Int J Radiat Oncol Biol Phys. 32:1995;287-292
2. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:2000;3904-3911
3. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-943
4. Sandler H., Pajak T., Hanks G., et al. Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02 [Abstract]. Proc Am Soc Clin Oncol. 22:2003;381
5. Shipley W.U., Lu J.D., Pilepich M.V., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys. 54:2002;1302-1310
6. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597
7. D'Amico A.V., Moul J., Carroll P.R., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 21:2003;2163-2172
8. Medical Research Council and Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 79:1997;235-246
9. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 52:2002;704-711
10. Lukka H., Warde P., Pickles T., et al. Controversies in prostate cancer radiotherapy Consensus development. Can J Urol. 8:2001;1314-1322
11. BC Cancer Agency, Cancer Management Manual. http://www.bccancer.bc.ca/ HPI/CancerManagementGuidelines/Genitourinary/Prostate/Management/HighRisk.htm. Last accessed Nov 2003
12. Pickles T., Duncan G.G., Kim-Sing C., et al. PSA relapse definitions - the Vancouver Rules show superior predictive power. Int J Radiat Oncol Biol Phys. 43:1999;699-700
13. Pickles T., Tyldesley S. Initiative PCO. PSA doubling time post-radiation The effect of prolonged neoadjuvant androgen ablation [Abstract]. Canad J Urol. 9:2002;1542
14. McLaren D.B., McKenzie M., Duncan G., et al. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer. 82:1998;342-348
15. Duchesne G.M., Millar J.L., Moraga V., et al. What to do for prostate cancer patients with a rising PSA? - A survey of Australian practice. Int J Radiat Oncol Biol Phys. 55:2003;986-991
16. Sylvester J., Grimm P., Blasco J., et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy A survey of practice patterns of urologists and radiation oncologists in the United States. Urology. 58:(2 Suppl. 1):2001;65-70
17. Kwan W., Pickles T. In regard to Kupelian et al.: Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52:704-711. Int J Radiat Oncol Biol Phys. 54:2002;1577-1579
18. Pollack A., Hanlon A.L., Movsas B., et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 57:2003;19-23
19. Lofters A., Juffs H.G., Pond G.R., et al. "PSA-itis:" Knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol. 168:2002;2516-2520
20. National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). PR7 Protocol: Intermittent vs continuous androgen suppression for pts with PSA progression in the clinical absence of distant metastases following radiotherapy for prostate cancer. http://www.ctg.queensu.ca/public/Clinical_Trials/ public_ph_3_trial_summary.html#PR7. Last accessed Oct 2003
21. Blackard C.E. The Veterans Administration Cooperative Urological Research Group studies of carcinoma of the prostate: A review. Cancer Chemother Rep. 59:1975;225-227
22. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate Immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment [comment]. J Urol. 166:2001;508-515
23. Kirk D. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer How safe is androgen deprivation? Br J Urol. 86:(Suppl.):2000;220